Skip to main content

Dismissed Risperdal Gynecomastia Lawsuit Reinstated

Dismissed Risperdal Gynecomastia Lawsuit Reinstated

Dismissed Risperdal Gynecomastia Lawsuit Reinstated

Introduction

A 2013 Risperdal lawsuit, filed by a man and his mother against Johnson & Johnson (J&J) and its subsidiary Janssen Pharmaceuticals for failing to provide adequate warnings regarding Risperdal’s potential to cause gynecomastia, which was dismissed in 2016, has been reinstated.

According to court documents, the man started using Risperdal in 2004 at the age of 7 and continued using the powerful antipsychotic medication until he was 10 years old. While on Risperdal, he developed female-like breasts, a condition known as gynecomastia. The lawsuit was later dismissed under Texas law by Judge Sean F. Kennedy, stating plaintiffs’ expert witness provided insufficient testimony against Risperdal.

On Tuesday, a 3-judge-panel of the Pennsylvania Superior Court ruled that the case should be evaluated under Pennsylvania law since it was procedural, thereby remanded the case back to Philadelphia and ordered a new trial.

In May, the Pennsylvania Supreme Court examined the level of public awareness regarding the dangers of Risperdal, which can put potential plaintiffs on notice to investigate their claims.

Nearly 7,000 gynecomastia lawsuits are pending in the Pennsylvania mass tort program. Two coordinated actions have been filed for Risperdal cases: one in Los Angeles Superior Court (Risperdal and Invega Product Liability Cases, JCCP 4775, presided by Honorable William Highberger) and the other in Philadelphia (In Re: Risperdal Litigation, March 2010 Term, Case No. 100300296).

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Purdue, Sacklers Agree to $7.4B Opioid Settlement

Categories: Opioids

Purdue Pharma and its owners, the Sackler family, have agreed to a $7.4 billion settlement to resolve thousands of lawsuits accusing the…

Paraquat Trials Scheduled for October 2025 & April 2026

Categories: Paraquat

A U.S. District Judge overseeing thousands of federal

UGA College of Pharmacy Gets $1M+ to Fight Opioid Crisis

Categories: Opioids

Faculty from the University of Georgia’s College of Pharmacy have been awarded a nearly $1.2 million grant from the Georgia Opioid Crisis…

Get 5 Free Medical Record Reviews – No Risk, No Contracts!      
Only 10 firms will be accepted!

Valid until February 28, 2025.